Table 1.
BL Demographics and Immunologic and Virologic outcomes at Week 48
| CD4 <= 350 | CD4 > 350 | Total | ||
|---|---|---|---|---|
| Sample Sizes | 148 | 173 | 321 | |
| Gender | Male | 128 (86%) | 143 (83%) | 271 (84%) |
| Race/Ethnicitya | White | 68 (46%) | 91 (53%) | 159 (50%) |
| Black | 50 (34%) | 61 (35%) | 111 (35%) | |
| Hispanic | 28 (19%) | 17 (10%) | 45 (14%) | |
| Asian | 2 (1%) | 4 (2%) | 6 (2%) | |
| Intravenous Drug Useb | 9 (6%) | 10 (6%) | 19 (6%) | |
| Age (years) | Median (min-max) | 37 (21–65) | 35 (17–60) | 36 (17–65) |
| CD4 count (cells/mm3) | median (Q1 - Q3) | 118.5 (37, 241) | 479 (413, 593) | 369 (135, 501) |
| Immunologic success (ΔCD448 ≥ 100 cells/mm3) | N (%) | 115 (78%) | 118 (68%) | 233/321 (73%) |
| HIV-1 RNA(log10 copies/mL) | Median (Q1 - Q3) | 5.26 (4.75, 5.66) | 4.44 (4.02, 4.92) | 4.83 (4.28, 5.40) |
| Proportion with RNA < 50 c/ml at week 48 | N (%) | 148 (100%) | 140 (81%) | 288/321 (90%) |
a
Intravenous drug use – ever (current or past)
b
Self-reported